Doolan, B.J. et al (2021) Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry. Australasian Journal of Dermatology. 2(1), e47-e54
M Rademaker et al (2019) Psoriasis and infection. A clinical practice narrative. Australasian Journal of Dermatology. 60(2), 91-98
Xie, K.K. et al (2018) Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments. Australasian Journal of Dermatology. 59(4), e247-252
Norris, D et al (2017) Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. Journal of Dermatological Treatment. 28(8), 731-736
Davila – Seijo, P. et al (2017). Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. ACTA Dermato- Venereologica 97(4), 516-518.
Nyugen, R. et al (2016) Five-year experience with infliximab: Follow up of the project familiarisation program. Australasian Journal of Dermatology 57, 300-306
Baker, C. et al (2013) Treatment goals for moderate to severe psoriasis: An Australian consensus (2013) Australasian Journal of Dermatology, 54, 148-154
Tan, E and Foley, P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis (2011) Australasian Journal of Dermatology 52(Suppl. 1), 11